Nicholas Saraceno, Senior Editor

Companies not included in the initial round are now pursuing their own agreements amid concerns over levies, Medicare pilot programs, and future price-setting policies.

In the second part of her Pharma Commerce video interview, Valerie Bandy, PharmD, Tecsys’ vice president of pharmacy solutions, points out that shortages remain the top disruption driver, revealing fragmented forecasting, limited enterprise visibility, and poor cross-system integration that keep hospitals stuck in reactive mode instead of proactive planning.

In today’s Pharma Pulse, the FDA issues a rare “Refusal-to-File" for Moderna’s influenza vaccine, while new research confirms GLP-1s act as potent tools against chronic inflammation.

The retailer is now accepting NovoCare savings programs for Wegovy and Ozempic, offering introductory discounts and adding access to oral Wegovy.

The feedback and knowledge of an editorial advisory board are critical to furthering the Pharmaceutical Commerce brand and enhancing industry-wide collaboration.

In the first part of her Pharma Commerce video interview, Valerie Bandy, PharmD, Tecsys’ vice president of pharmacy solutions, explains why health systems lack real-time pharmacy inventory visibility, driving reactive decisions, higher costs, and increased vulnerability to shortages and disruptions.

In today’s Pharma Pulse, the American College of Physicians issues a formal rejection of the term "provider," while Takeda partners with Iambic Therapeutics to accelerate small-molecule discovery through AI.

Sector leaders explore how third-party logistics providers are adapting to advanced therapies, tighter regulations, digital transformation, and expanding cold chain demands.

As policy pressure, tariffs, and supply chain risks push drugmakers to expand US-based production, this FAQ explains what pharma reshoring is, why it’s accelerating, which companies are investing, and how the shift could reshape reliability, regulation, and patient access.

In today’s Pharma Pulse, a telehealth giant retreats from the weight loss pill conflict, while safety-net hospitals secure a major legal victory against 340B reform.

SQ Innovation’s at-home furosemide injection for heart failure–related edema is now available through two of the Big Three drug wholesalers and covered under a Medicaid rebate agreement, expanding access for hospitals, pharmacies, and eligible patients.

In today’s Pharma Pulse, TrumpRx officially goes live, while Novo Nordisk prepares to take the oral version of Wegovy to the biggest stage in advertising.

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.

A landmark FTC settlement requires Express Scripts to overhaul formulary and rebate practices, boosting price transparency in the process.

At Trade & Channel Strategies, industry executives explored evolving channel models, serialization challenges, generics and biosimilars, and the strategies shaping pharma's future.

In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, while Novartis braces for the largest patent expiration cycle in its history.

In the final part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, outlines how real-time AI signal sharing across supply chain partners can help pharma companies anticipate demand shifts, reduce shortages, and respond faster to pandemics and geopolitical disruptions.

In today’s Pharma Pulse, AstraZeneca faces a complete response letter for its self-injectable lupus drug, while the EMA gives the green light to a historic wave of new therapies for MASH, rare diseases, and postmenopause.

The acquisition expands ORBIS’ manufacturing capacity and technical expertise in reusable plastic pallets, lids, and trays, enabling faster design, prototyping, and production for pharma and broader supply chain applications.

In the third part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains why independent verification, validation, and human decision-making must stay central, as AI accelerates data processing and operational workflows across pharma supply chains.

In today’s Pharma Pulse, the FDA launches its "PreCheck" pilot to speed up domestic factory approvals, while new SELECT trial data shows that semaglutide significantly slashes hospital admission rates.

The deal strengthens Körber’s SAP supply chain and digital manufacturing consulting portfolio, extends its global footprint, and creates Körber Stellium to deliver end-to-end supply chain and software solutions.

In the second part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, notes that in order to reduce risk and accelerate adoption, supply chain leaders can begin applying AI to machine-generated data—such as IoT sensor outputs—where insights improve performance without raising concerns about data ownership, security, or competitive exposure.

In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.

This guide breaks down how AFPs function and why they are fundamentally changing the path between patients and their therapies.

In the first part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains how pharma leaders can detect early warning signs beyond their own silos and adapt before disruption becomes unavoidable.

In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.

For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.

In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.